AYTU BioPharma
AYTU
27 hedge funds and large institutions have $5.99M invested in AYTU BioPharma in 2024 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 6 reducing their positions, and 3 closing their positions.
10% more capital invested
Capital invested by funds: $5.46M → $5.99M (+$537K)
2.17% more ownership
Funds ownership: 32.23% → 34.4% (+2.2%)
0% more funds holding
Funds holding: 27 → 27 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
0% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$761K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$29.1K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$25.1K |
| 4 |
Renaissance Technologies
New York
|
+$8.45K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$4.09K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$42.2K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$3.21K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$2.17K |
| 4 |
Morgan Stanley
New York
|
-$1.87K |
| 5 |
JP Morgan Chase
New York
|
-$241 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SIC
26
SJS Investment Consulting
Sylvania,
Ohio
| $15 | +$15 | +5 | New |
|
|
27
Goldman Sachs
New York
| – | -$42.2K | -13,882 | Closed |
|
|
WFA
28
West Financial Advisors
Des Moines,
Iowa
| – | -$31 | -10 | Closed |
|
29
Fidelity Investments
Boston,
Massachusetts
| – | -$6 | -2 | Closed |
|
AYTU Hedge Fund Activity: Q2 2024 in Review
27 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in AYTU BioPharma (AYTU) for Q2 2024, worth a combined $5.99M — up 9.8% from $5.46M a quarter earlier.
Fund positioning in AYTU was balanced in Q2 2024: 3 funds opened new positions, 3 closed out, 6 added to existing stakes and 6 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $761K. The largest seller was Goldman Sachs, exiting entirely with an estimated $42.2K sold.
- 27 institutional investors held AYTU BioPharma (AYTU) as of Q2 2024, unchanged from Q1 2024.
- Funds reported $5.99M of AYTU BioPharma stock for Q2 2024, up 9.8% quarter-over-quarter.
- 3 funds opened new AYTU BioPharma positions in Q2 2024 and 3 closed out, a net change of 0 holders.
- The largest AYTU BioPharma buyer in Q2 2024 was Armistice Capital, an estimated $761K added.
- The largest AYTU BioPharma seller in Q2 2024 was Goldman Sachs, an estimated $42.2K sold.
Based on aggregated 13F filings for Q2 2024.